Table 2:
Patient characteristics: Clinical features and comorbidities.
| All (2010–2019) n = 489 |
Group 1 (2010–2015) n = 132 |
Group 2 (2016–2017) n = 155 |
Group 3 (2018–2019) n = 202 |
p value | |
|---|---|---|---|---|---|
| Clinical features | |||||
|
| |||||
| NYHA class | 0.164 | ||||
|
| |||||
| NYHA I - n (%) | 2 (0.4 %) | 2 (1.5 %) | 0 (0.0 %) | 0 (0.0 %) | |
|
| |||||
| NYHA II - n (%) | 61 (12.5 %) | 17 (12.9 %) | 22 (14.2 %) | 22 (10.9 %) | |
|
| |||||
| NYHA III - n (%) | 370 (75.7 %) | 94 (71.2 %) | 114 (73.5 %) | 162 (80.2 %) | |
|
| |||||
| NYHA IV - n (%) | 52 (10.6 %) | 17 (12.9 %) | 19 (12.3 %) | 16 (7.9 %) | |
|
| |||||
| CCS class | < 0.001 | ||||
|
| |||||
| CCS I - n (%) | 15 (3.1 %) | 3 (2.3 %) | 1 (0.6 %) | 11 (5.4 %) | |
|
| |||||
| CCS II - n (%) | 233 (47.6 %) | 34 (25.8 %) | 114 (73.5 %) | 85 (42.1 %) | |
|
| |||||
| CCS III - n (%) | 62 (12.7 %) | 47 (35.6 %) | 10 (6.5 %) | 5 (2.5 %) | |
|
| |||||
| CCS IV - n (%) | 1 (0.2 %) | 1 (0.8 %) | 0 (0.0 %) | 0 (0.0 %) | |
|
| |||||
| Cardiac decompensation - n (%) | 177 (36.2 %) | 60 (45.5 %) | 54 (34.8 %) | 63 (31.2 %) | 0.027 |
|
| |||||
| Comorbidities | |||||
|
| |||||
| Coronary artery disease - n (%) | 0.433 | ||||
|
| |||||
| - 1-vessel disease - n (%) | 100 (20.4 %) | 27 (20.5 %) | 31 (20.0 %) | 42 (20.8 %) | |
| - 2-vessel disease - n (%) | 70 (14.3 %) | 15 (11.4 %) | 23 (14.8 %) | 32 (15.8 %) | |
| - 3-vessel disease - n (%) | 112 (22.9 %) | 38 (28.8 %) | 29 (18.7 %) | 45 (22.3 %) | |
| - left main artery stenosis - n (%) | 21 (4.3 %) | 8 (6.1 %) | 9 (5.8 %) | 4 (2.0 %) | |
|
| |||||
| Previous myocardial infarction | 0.018 | ||||
|
| |||||
| - no myocardial infarction | 68 (13.9 %) | 28 (21.2 %) | 17 (11.0 %) | 23 (11.4 %) | |
|
| |||||
| - STEMI – n (%) | 32 (6.5 %) | 17 (12.9 %) | 6 (3.9 %) | 9 (4.5 %) | |
|
| |||||
| - NSTEMI – n (%) | 34 (7.0 %) | 13 (9.8 %) | 10 (6.5 %) | 11 (5.4 %) | |
|
| |||||
| Previous bypass operation- n (%) | 79 (16.2 %) | 33 (25.0 %) | 17 (11.0 %) | 29 (14.4 %) | 0.004 |
|
| |||||
| Previous valve operation - n (%) | 14 (2.9 %) | 4 (3.0 %) | 3 (1.9 %) | 7 (3.5 %) | 0.685 |
|
| |||||
| Previous balloon valvuloplasty - n (%) | 37 (7.6 %) | 1 (0.8 %) | 16 (10.3 %) | 20 (9.9 %) | 0.002 |
|
| |||||
| Previous PCI - n (%) | 199 (40.7 %) | 57 (43.2 %) | 60 (38.7 %) | 82 (40.6 %) | 0.744 |
|
| |||||
| PVD - n (%) | 118 (24.1 %) | 51 (38.6 %) | 37 (23.9 %) | 30 (14.9 %) | < 0.001 |
|
| |||||
| CVD - n (%) | 62 (12.7 %) | 30 (22.7 %) | 15 (9.7 %) | 17 (8.4 %) | < 0.001 |
|
| |||||
| COPD - n (%) | 57 (11.7 %) | 18 (13.6 %) | 14 (9.0 %) | 25 (12.4 %) | 0.440 |
|
| |||||
| Previous stroke - n (%) | 51 (10.4 %) | 19 (14.4 %) | 15 (9.7 %) | 17 (8.4 %) | 0.203 |
|
| |||||
| History of cancer - n (%) | 123 (25.2 %) | 28 (21.2 %) | 51 (32.9 %) | 44 (21.8 %) | 0.027 |
|
| |||||
| Anemia – n (%) | 230 (47.1 %) | 77 (58.3 %) | 67 (43.5 %) | 86 (42.6 %) | 0.010 |
Abbreviations: CCS = Canadian Cardiovascular Society; COPD = chronic obstructive pulmonary disease; CVD = cerebrovascular disease; NSTEMI = Non-ST-elevation myocardial infarction; NYHA = New York Heart Association; PCI = percutaneous coronary intervention; PVD = peripheral vascular disease; STEMI = ST-elevation myocardial infarction.